Literature DB >> 3014743

Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurization.

J Hilfenhaus, A Herrmann, R Mauler, A M Prince.   

Abstract

Heat treatment at 60 degrees C for 10 h in solution (pasteurization) was introduced into the manufacturing process of antihemophilic cryoprecipitate (AHC) and factor VIII concentrates (F VIII) to reduce the risk of transmission of hepatitis to hemophiliacs. Since the acquired immunodeficiency syndrome (AIDS) may also be transmitted to hemophiliacs by antihemophilic plasma protein preparations, we have investigated inactivation of the AIDS virus HTLV III by pasteurization in AHC or F VIII and included in this study cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), poliovirus and vaccinia virus. Each of these viruses was efficiently inactivated by pasteurization although considerable differences were observed between the different viruses HTLV III was rapidly inactivated, becoming nondetectable within 30-60 min. Our findings indicate that pasteurized AHC or F VIII should have a high margin of safety regarding the transmission of AIDS or any other infectious disease caused by viruses such as those tested.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014743     DOI: 10.1111/j.1423-0410.1986.tb04882.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

1.  HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate.

Authors:  R S Remis; M V O'Shaughnessy; C Tsoukas; G H Growe; M T Schechter; R W Palmer; D N Lawrence
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

2.  Comparative study of inactivation of herpes simplex virus types 1 and 2 by commonly used antiseptic agents.

Authors:  W S Croughan; A M Behbehani
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

3.  The infectious complications of blood transfusion.

Authors:  N A Buskard
Journal:  Can Fam Physician       Date:  1987-05       Impact factor: 3.275

Review 4.  The development of virus-free labile blood derivatives--a review.

Authors:  A M Prince; B Horowitz; M S Horowitz; E Zang
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

Review 5.  Pathogen safety of plasma-derived products - Haemate P/Humate-P.

Authors:  A Gröner
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.